- Home
- ZIM vs CELC Comparison
ZIM vs CELC Comparison
Compare ZIM & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZIM | CELC |
|---|---|---|
| Founded | 1945 | 2011 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.1B |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ZIM | CELC |
|---|---|---|
| Price | $26.99 | $122.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $19.26 | ★ $107.88 |
| AVG Volume (30 Days) | ★ 1.4M | 661.2K |
| Earning Date | 05-18-2026 | 05-13-2026 |
| Dividend Yield | ★ 7.38% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $720.19 |
| P/E Ratio | $3.49 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.33 | $9.64 |
| 52 Week High | $29.97 | $127.34 |
Technical Indicators
Market Signals| Indicator | ZIM | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 56.31 | 57.50 |
| Support Level | $25.77 | $99.38 |
| Resistance Level | $29.13 | N/A |
| Average True Range (ATR) | 0.45 | 5.29 |
| MACD | 0.05 | 0.90 |
| Stochastic Oscillator | 80.33 | 75.39 |
Price Performance
Historical ComparisonAbout ZIM ZIM Integrated Shipping Services Ltd.
ZIM Integrated Shipping Services Ltd is an asset-light container liner shipping company. It offers tailored services, including land transportation and logistical services, specialized shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. Its services include Cargo Services, Digital Services, Schedules, and Shipping Trades and Lines. Geographically, it derives a majority of its revenue from the Pacific trade region.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.